Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03136965 · ClinicalTrials.gov registry record · Phase 2
Platelet-Rich Plasma Therapy for Patellar Tendinopathy
A Phase 2 study of Patellar Tendinitis, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03136965: Completed Phase 2 study of Patellar Tendinitis, sponsored by University of Wisconsin, Madison.
NCT03136965 is a Phase 2 study of Patellar Tendinitis that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03136965, a Phase 2 study of Patellar Tendinitis, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this research is to find an effective treatment for patellar tendinopathy (PT). To achieve this, we will conduct a double-blinded randomized controlled trial to investigate if platelet-rich plasma is effective for treatment. Clinical (pain and function scores) and bio-mechanical (knee strength) measures will be correlated with disease modification changes assessed using conventional and novel quantitative magnetic resonance imaging (MRI) and ultrasound (US) techniques.
Primary Outcome
A quality of life measure, the Victoria Institute of Sport Assessment - Patellar Tendon (VISA-P) will be used to evaluate pain before and after the intervention. The instrument is scored from 0-100 with higher scores indicating less pain.
Conditions Studied
Interventions
- PROCEDURE Dry Needling
- BIOLOGICAL PRP
- PROCEDURE Dry Needling - Sham
Study Locations (1)
Wisconsin
- University of Wisconsin, Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-04-25 |
| Est. Completion | 2022-08-15 |
| Phase | Phase 2 |
What the finished NCT03136965 record still lists
NCT03136965 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Patellar Tendinitis appearing as the primary indexed condition, and to 3 interventions - of which Dry Needling is the first listed.
NCT03136965 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03136965 about?
NCT03136965 is a clinical study titled "Platelet-Rich Plasma Therapy for Patellar Tendinopathy". The overall goal of this research is to find an effective treatment for patellar tendinopathy (PT). To achieve this, we will conduct a double-blinded randomized controlled trial to investigate if platelet-rich plasma is effective for treatment. Clinical (pain and function scores) and bio-mechanical ...
What is the current status of trial NCT03136965?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2017-04-25. Estimated completion is 2022-08-15.
What conditions does trial NCT03136965 study?
This clinical trial studies the following conditions: Patellar Tendinitis.
What interventions are being tested in trial NCT03136965?
The interventions under investigation include: Dry Needling (PROCEDURE), PRP (BIOLOGICAL), Dry Needling - Sham (PROCEDURE).
Who is sponsoring clinical trial NCT03136965?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03136965 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03136965's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI